Intuitive Surgical’s post-earnings selloff looks overdone because the market is trading a slowdown headline as if the franchise cracked. It didn’t. Q2 revenue still climbed 19% to $2.89 billion, worldwide procedures grew about 16%, and da Vinci 5 placements reached 246 in the quarter. When a company with a 95 Profitability score and 90 Growth score inside the TickerSpark Score gets punished 14.1% on numbers like that, we see a reset in expectations, not a break in the story.
The cleanest reason to stay constructive is that the core engine is still compounding. Intuitive’s installed base reached 11,710 da Vinci systems as of June 30, up 12% year over year, while Ion’s installed base rose 21% to 1,096. That matters because a larger base feeds recurring instruments, accessories, service revenue, and future upgrades, which is exactly why this business keeps producing elite margins, including a 66.3% gross margin and 30.5% operating margin.
The upgrade cycle is also real, not theoretical. Da Vinci 5 placements hit 246 in Q2, up from 180 a year earlier, after 232 placements in Q1 versus 147 in the prior-year quarter. That is the number the market should be obsessing over, because it shows hospitals are still adopting the newest platform even as investors fixate on one quarter of softer U.S. procedure growth. If da Vinci 5 is the real story, then this quarter supported the bull case.
The growth profile still looks stronger than the selloff implies. Full-year revenue growth is running at 20.5%, EPS growth at 22.3%, and net income growth at 23.0%, while the company has now beaten consensus EPS in 8 straight quarters. Even after the drop, this is not some low-quality multiple trap; it is a premium medical device franchise with an Overall TickerSpark Score of 70, dragged down mostly by weak Momentum at 30 after the collapse in the share price. Against a peer like RGEN, which trades at 81.81 times earnings with just 16.4% revenue growth and a 6.7% net margin, ISRG’s 39.03 P/E and 28.2% net margin look a lot more defensible.
The market is not inventing the concern out of thin air. U.S. procedure growth slowed to 12% in Q2 from 14% in Q1, and management flagged insurance-plan changes and subsidy expiration as possible demand headwinds. On top of that, the company kept its full-year da Vinci procedure growth outlook at 13.5% to 15.5% and said results should land near the midpoint, which is not the kind of guidance raise that usually supports a premium multiple.
That is the real risk here: not that Intuitive is broken, but that a stock with an 11.09 price-to-sales ratio and a 39.03 P/E can still get cheaper if growth merely stays good instead of reaccelerating. The technical picture is ugly too, with ISRG below its 20-day, 50-day, and 200-day moving averages and an RSI of 30.16. Even so, those are reasons to expect volatility, not reasons to confuse a valuation reset with a fundamental unwind.
What matters now is whether the next quarter confirms that Q2 was a deceleration inside a healthy growth curve rather than the start of a deeper demand problem. We would watch three things closely: worldwide procedure growth staying in the mid-teens, da Vinci 5 placements holding near the current 246 pace, and any sign that U.S. softness tied to insurance changes is stabilizing rather than spreading. If those hold, this selloff will look like a gift to buyers who wanted a better entry into a dominant franchise.
We would not chase blindly just because the stock is down 14%, especially with Momentum at 30 and the chart still damaged. But the business is still putting up 19% quarterly revenue growth, expanding its installed base, and defending industry-leading margins. Our take is simple: ISRG looks more attractive after this washout, not less, and we would rather own this franchise than reach for weaker medtech growth stories at comparable or richer valuations.
